Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

CVS Health : Expanding Access to Naloxone Saves Lives

share with twitter share with LinkedIn share with facebook
share via e-mail
06/12/2017 | 12:28pm CET

Release date- 09062017 - CVS Health - Expanding Access to Naloxone Saves Lives.

According to the Centers for Disease Control and Prevention, more than 50,000 people died from drug overdoses in the U.S. in 2015.1 More than 60 percent involved an opioid.2

We know that Americans from all walks of life are finding that prescription drug abuse is hitting closer and closer to home; nearly one in three Americans report that they have been personally affected, according to a recent survey conducted by CVS Health.

While abuse-prevention education and outreach programs are vital for curbing drug misuse and abuse, one strategy that can help communities address overdoses in the moment is ensuring access to the life-saving drug naloxone.

What is Naloxone?

Naloxone, also known by the brand name Narcan, is a lifesaving drug that blocks opioid receptor sites to reverse the effects of an overdose.3 Over the past two years CVS Health has worked to expand access to naloxone without individual prescriptions in 41 states, most recently to CVS Pharmacy patients in Arizona.

Increasing Access to Naloxone Saves Lives

Many states have recently passed Naloxone Access Laws (NALs) that widen access to naloxone by providing specific statutory protections for nonmedical professionals to possess and administer naloxone without a prescription. This enables any person without a prescription to have naloxone and to give it to a person showing signs of an opioid overdose without having to fear legal repercussions.4

According to the National Bureau of Economic Research (NBER),5 states that have adopted NALs have seen a nine to 11 percent reduction in opioid-related deaths. This research underscores the importance of increasing access to naloxone as part of a larger strategy to address the impact of prescription drug abuse.

Community Leaders Amplify Naloxone's Value

During an event hosted by CVS Health, Arizona State Attorney General Mark Brnovich and State Representative Heather Carter joined CVS Health in announcing that naloxone would be available at all Arizona CVS Pharmacy locations without a prescription. Their remarks echoed the importance of naloxone in addressing prescription drug abuse and opioid abuse more broadly.

'The opioid epidemic is an urgent public health crisis facing Arizona and the entire country,' said Attorney General Brnovich. 'We want to ensure that Arizona families who have loved ones struggling with addiction have access to naloxone because it saves lives.'

Representative Carter, a sponsor of the naloxone access legislation signed into law last year, added, 'The main purpose behind the legislation I sponsored was to get this medication in the hands of a person who may have an opportunity to save a life.'

Our Ongoing Work

Opioid abuse is an epidemic that does not discriminate, and it continues to be an area of great concern and focus for CVS Health. There is no single cause to the problem, and the solution will require a multipronged effort including pharmacy, physicians, the pharmaceutical industry and government.

In addition to expanding access to naloxone, CVS Health is working to help communities address prescription drug abuse through education, outreach and safe medication disposal:

CVS Health's Medication Disposal for Safer Communities Program has donated more than 750 collection units to law enforcement partners across the country, allowing for the safe disposal of more than 80 metric tons of unwanted medication. This program offers an online search tool through which anyone can find a drop box location near them.

Pharmacists volunteering through the company's Pharmacists Teach program have helped educate more than 250,000 students about the dangers of prescription drug abuse.

For more information about our efforts in the fight against opioid abuse, visit our Prescription Drug Abuse information center. And to stay informed about the most talked-about topics in health care, register for content alerts and our bi-weekly health care newsletter.

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CVS HEALTH
12/14 CVS HEALTH : chief information officer resigns
12/14 CVS HEALTH : Foundation Announces Grant to Increase Access to Provider Education..
12/14 CVS HEALTH : Solera Health Expands Its Board of Directors with the Addition of H..
12/12 CVS HEALTH : 3 Reasons Why Florida Addiction Recovery Center CEO Is Wary Of $77 ..
12/11 CVS HEALTH : 3 Reasons Why Florida Addiction Recovery Center CEO Is Wary Of $77 ..
12/08 CVS expects U.S. Justice Department to handle review of Aetna deal
12/08 CVS HEALTH : A.M. Best Places Credit Ratings of SilverScript Insurance Company U..
12/08 CVS HEALTH : Greg's Pharmacy, Bluffton, will become a CVS Pharmacy
12/07 MYERS INDUSTRIES : Names Chris DuPaul as Group President, Distribution
12/07 CVS HEALTH : Meningitis B Vaccine Available to Students, Faculty and Staff at UM..
More news
News from SeekingAlpha
12/15 Just Turned 40? How To Reach A Goal Of $1.5 Million.
12/15 MY JOURNEY TO FINANCIAL INDEPENDENCE : 86-Stock November Portfolio Update - Buyi..
12/14 The Next 20 Dividend Achievers Absolutely Trounce The Market
12/14 WALGREENS BOOTS ALLIANCE : Trading At A Bargain
12/13 The Value Of Reliability And Why Omega Healthcare Is A Value Trap
Financials ($)
Sales 2017 184 B
EBIT 2017 9 955 M
Net income 2017 5 255 M
Debt 2017 24 517 M
Yield 2017 2,81%
P/E ratio 2017 14,11
P/E ratio 2018 12,39
EV / Sales 2017 0,52x
EV / Sales 2018 0,49x
Capitalization 71 720 M
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 86,1 $
Spread / Average Target 22%
EPS Revisions
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-9.24%71 720